title: An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
abstract: An experimental model of tumor dormancy therapy for advanced head and neck carcinoma was developed. After transplantation of KB cells into nude mice, the mice were given tiracoxib, a selective cyclooxygenase (COX)-2 inhibitor, probucol, an antioxidant, and S-1, an oral pro-drug of 5-fluorouracil (5-FU), or combinations of two of them. The combined administration of tiracoxib with probucol significantly inhibited the tumor growth. The angiogenesis in this group was markedly reduced. Tiracoxib and probucol did not affect the intratumoral concentration of 5-FU when coadministered with S-1. The combined use of tiracoxib and probucol is thus a candidate for use in maintenance therapy after the primary therapy for patients with advanced head and neck carcinoma.
authors.affiliation: Department of Otorhinolaryngology, Yokohama City University School of Medicine, Kanazawa-ku, Yokohama 236-0004, Japan. go_c@med.yokohama-cu.ac.jp
authors.forename: G
authors.initials: G
authors.lastname: Nishimura
authors.forename: S
authors.initials: S
authors.lastname: Yanoma
authors.forename: K
authors.initials: K
authors.lastname: Satake
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
authors.forename: T
authors.initials: T
authors.lastname: Taguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: F
authors.initials: F
authors.lastname: Hirose
authors.forename: M
authors.initials: M
authors.lastname: Tsukuda
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001711:Biotransformation; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000493:pharmacokinetics; D006258:Head and Neck Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008565:Membrane Proteins; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009930:Organic Chemicals; D010094:Oxonic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011341:Probucol / Q000008:administration & dosage / Q000494:pharmacology*; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics; D011451:Prostaglandin-Endoperoxide Synthases; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D005641:Tegafur / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D019098:Telomerase / Q000037:antagonists & inhibitors / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D000964:Antimetabolites, Antineoplastic; D000975:Antioxidants; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004338:Drug Combinations; D007527:Isoenzymes; D008565:Membrane Proteins; D009930:Organic Chemicals; D011355:Prodrugs; D011725:Pyridines; C419232:tiracoxib; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D019098:Telomerase; D011341:Probucol; D005472:Fluorouracil